Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

[A case of the patient with HBeAg-negative chronic hepatitis B recurrence after retreatment with adefovir occurred HBsAg seroconversion].

Zhou P, Li XJ.

Zhonghua Gan Zang Bing Za Zhi. 2013 Dec;21(12):955-6. Chinese. No abstract available.

PMID:
24660255
2.

A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir.

Ha M, Zhang G, Diao S, Lin M, Sun L, She H, Kuan C, Shen L, Huang C, Shen W, Huang Z.

Arch Virol. 2012 Feb;157(2):285-90. doi: 10.1007/s00705-011-1163-0. Epub 2011 Nov 15.

PMID:
22080196
3.

Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment.

Singh AK, Sharma MK, Hissar SS, Gupta E, Sarin SK.

J Viral Hepat. 2014 Jun;21(6):439-46. doi: 10.1111/jvh.12149. Epub 2013 Aug 26.

PMID:
24750522
4.

Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.

Maklad S, Doss W, El Din SS, Hassan K, Zeid AA.

Arab J Gastroenterol. 2014 Mar;15(1):1-5. doi: 10.1016/j.ajg.2014.01.003. Epub 2014 Feb 4.

PMID:
24630505
5.

[Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].

Zhou HJ, Li SG, Wen FY, Yang XY, Wu JL, Tan B, Fu J.

Zhonghua Gan Zang Bing Za Zhi. 2009 Aug;17(8):564-8. Chinese.

PMID:
19719911
6.

HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy.

Tseng KC, Cheng PN, Wu IC, Chang CK, Chou AL, Liu WC, Chang TT.

Hepatogastroenterology. 2009 May-Jun;56(91-92):813-8.

PMID:
19621708
7.

Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants.

Wu IC, Shiffman ML, Tong MJ, Marcellin P, Mondou E, Frederick D, Snow-Lampart A, Sorbel J, Rousseau F, Chang TT.

Clin Infect Dis. 2008 Nov 15;47(10):1305-11. doi: 10.1086/592570.

PMID:
18840078
8.

Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.

Boglione L, D'Avolio A, Cariti G, Gregori G, Burdino E, Baietto L, Cusato J, Ghisetti V, De Rosa FG, Di Perri G.

Liver Int. 2013 Apr;33(4):580-5. doi: 10.1111/liv.12091. Epub 2013 Jan 14.

PMID:
23311449
9.

What is the optimum dose of adefovir in the treatment of chronic hepatitis B infection?

Simsek H, Shorbagi A, Balaban Y, Tatar G.

J Hepatol. 2008 Sep;49(3):464-5. doi: 10.1016/j.jhep.2008.06.013. Epub 2008 Jul 3. No abstract available.

10.

[Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B].

Mateos ML, Tato M, Moreira V.

Gastroenterol Hepatol. 2006 Feb;29(2):71-3. Spanish.

PMID:
16448607
11.

Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study.

Lu H, Geng da Y, Shen F, Zhang JY, Lu B, Ma LX.

Virol J. 2011 Sep 21;8:444. doi: 10.1186/1743-422X-8-444.

12.

[Relationship between HBeAg seroconversion with genotypes and HBV specific CTL in patients with chronic hepatitis B treated with Adefovir dipivoxil].

Zhou YL, Wang XC, Wu YT, Tan YF, Zhao YP, Tang JM, Pan JQ, Yang ZX, Gu XB.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2011 Jun;25(3):220-3. Chinese.

PMID:
21977598
13.

[Efficacy and safety of telbivudine and adefovir dipivoxil for the treatment of chronic hepatitis B patients with high level hepatitis B virus load and hepatitis B e antigen-positivity].

Li Y, Chen ZT, Wu JC, Gan JH, Chen JJ, Zhao WF, Luo EP.

Zhonghua Gan Zang Bing Za Zhi. 2012 Nov;20(11):859-60. Chinese. No abstract available.

PMID:
23401889
14.

Serum levels of surface large envelope proteins: prognostic markers for hepatitis B e antigen-negative patients with adefovir dipivoxil treatment.

Fan X, Fang D, Bin D, Xueyong L, Jun C, Hongshan W.

Antivir Ther. 2009;14(8):1149-56. doi: 10.3851/IMP1456.

PMID:
20032544
15.

De novo combination therapy adefovir plus lamivudine as a treatment for women of child-bearing age with HBeAg-positive chronic hepatitis B before pregnancy.

Ma LN, Ding XC, Liu XY, Xu CQ, Liu SW, Yan X.

J Med Virol. 2014 Mar;86(3):433-6. doi: 10.1002/jmv.23828. Epub 2013 Oct 25.

PMID:
24166586
16.

[Promotion of HBeAg seroconversion/loss in patients with chronic hepatitis B following the switch from nucleoside drugs to telbivudine and adefovir].

Cui S, Wang M, Gong Y.

Zhonghua Gan Zang Bing Za Zhi. 2014 Oct;22(10):776-8. Chinese. No abstract available.

PMID:
25558499
17.

Treatment of patients with chronic hepatitis B with adefovir dipivoxil.

Tong MJ, Tu SS.

Semin Liver Dis. 2004;24 Suppl 1:37-44. Review.

PMID:
15192800
18.

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

Mohamadnejad M.

Arch Iran Med. 2006 Jan;9(1):90-2. No abstract available.

PMID:
16649389
19.

Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B.

Minde Z, Yimin M, Guangbi Y, JinLin H, Hao W, Hong R, Yuming W, Xiaqiu Z, Daozhen X, Yagang C, Junqi N, Youming C, Yaozong W, Dixon J, Barker K.

Liver Int. 2012 Jan;32(1):137-46. doi: 10.1111/j.1478-3231.2011.02641.x. Epub 2011 Sep 19.

PMID:
22097972

Supplemental Content

Support Center